Browsing Tag
New York
187 posts
Ørsted’s $9.35bn rescue plan: Can the offshore wind pioneer weather America’s energy politics?
Find out how Ørsted’s $9.35B rights issue aims to rescue its U.S. offshore wind projects and whether it can withstand America’s shifting energy politics.
Fire at Novelis aluminum plant threatens Ford’s supply chain and U.S. automakers’ production
A major fire at Novelis’ Oswego plant could disrupt Ford’s aluminum supply chain for months. Find out how automakers are racing to contain the impact.
What Cushman & Wakefield’s $840m term loan repricing really signals about CRE finance
Cushman & Wakefield (NYSE: CWK) cuts borrowing costs by repricing $840M in debt. Learn how this debt strategy shapes investor sentiment and balance sheet outlook.
Hudson tunnel project secures $665mn contract extension as MPA Delivery Partners push transformational U.S. rail milestone
MPA Delivery Partners secures $665M extension for the Hudson Tunnel Project, reinforcing U.S. rail renewal and boosting Parsons and Arcadis stocks.
From static cover to smart insights: How Bondaval and Swiss Re plan to reinvent credit insurance
Bondaval partners with Swiss Re Corporate Solutions to launch data-driven credit risk solutions for corporates. Find out how this fintech-insurer tie-up could reshape global credit insurance.
Can Uzbekistan Airways’ $8.5bn Boeing Dreamliner bet turn Tashkent into a global long-haul hub?
Uzbekistan Airways orders up to 22 Boeing 787-9 Dreamliners worth $8.5B, reshaping Central Asia’s aviation hub ambitions and lifting Boeing’s backlog.
New York’s largest business incubator opens in downtown Syracuse with $32mn INSPYRE Innovation Hub
New York’s $32M INSPYRE Innovation Hub opens in Syracuse. See how CenterState CEO plans to scale startups and reshape Central New York’s economy today.
Pfizer to buy Metsera in $7.3bn obesity drug deal, challenging Lilly and Novo
Pfizer’s $7.3B Metsera takeover could reshape the GLP-1 obesity drug race and challenge Eli Lilly and Novo Nordisk’s dominance in weight loss treatments.
Why Rithm Capital’s $1.6bn Paramount deal triggered a sharp stock drop for PGRE investors
Rithm Capital is acquiring Paramount Group for $1.6B, but Paramount stock dropped 11%. Discover why investors reacted this way and what it means next.
Tronox just raised $400m at 9.125%—but is it refinancing smart or a warning sign?
Tronox raises $400M via 9.125% notes to refinance debt. Explore what this means for its balance sheet, stock, and the titanium dioxide industry.